Articles tagged with Colorectal Cancer
Researchers have developed a new risk assessment scoring system to stratify risk for advanced neoplasia in asymptomatic adults. The study found that patients with lower risk scores may be suitable for less invasive tests such as sigmoidoscopies or occult blood tests.
A study found that examining the right side of the colon while patients lie on their left side increases polyp and adenoma detection. This position change also improved distension of the colon, allowing for better visualization. The results suggest a more effective tool for ongoing surveillance and prevention.
Researchers analyzed data from patients undergoing stage IV colorectal cancer surgery to identify benchmarks for surgical practice. They found that major complications vary depending on the extent of liver resection and type of colorectal surgery performed.
A research team has discovered a mechanism to mimic a viral infection in colon cancer stem cells, which could potentially trigger an immune response to fight the disease. Decitabine, a chemotherapy drug, is identified as a potential target to induce viral mimicry and activate an anti-viral response.
A new testing method developed to accurately detect PMS2 gene mutations has been shown to improve diagnosis and support genetic counseling and medical management for individuals with Lynch syndrome. The approach combines targeted capture next-generation sequencing, multiplex ligation-dependent probe amplification, and long-range PCR fo...
A population-based case-control study found that long-term, continuous use of low-dose aspirin and nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with decreased colorectal cancer risk. The study also suggests that higher COX-2 selectivity in nonaspirin NSAIDs may offer greater protection.
The European Society for Medical Oncology (ESMO) announced the award of its esteemed prizes to three exceptional medical oncologists: Nathan Cherny, Nagahiro Saijo, and Cornelis Punt. These pioneers have made groundbreaking contributions to palliative care integration, medical oncology in Asia, and immunotherapy approaches.
Researchers at Arizona State University have identified a link between chronic inflammation and colon cancer metastasis. The study found that prostaglandin E2 (PGE2) triggers the spread of cancer cells to other organs, leading to increased tumor burden and chemotherapy resistance.
Researchers at VIB and KU Leuven found that inhibiting PHD1 prevents p53 activation, leading to improved response to chemotherapy in colorectal cancer cells. This discovery offers new therapeutic potential for increasing sensitivity to chemotherapeutic treatments.
A study at the University of Texas MD Anderson Cancer Center found that CSN6 is overexpressed in colorectal cancer tissue samples, leading to poor survival rates. The biomarker's deregulation can lead to cancer development through cellular signaling pathways.
A new study reveals that Louisiana's colorectal cancer incidence and mortality rates would drop significantly if the state had the same risk factors, screening rates, and survival rates as New Jersey. With these changes, Louisiana's rates would be lower than those in New Jersey, essentially reversing recent trends.
Researchers found that 35% of patients with early-onset colorectal cancer (diagnosed before age 35) have a genetic disease, highlighting the need for genetic counseling to identify high-risk family members. Gene panel testing is recommended to uncover underlying mutations, allowing for preventive measures and earlier screening.
A new study by Georgia State University researchers found that state regulations significantly influence when patients receive cancer diagnoses, particularly among people under 65. The study suggests that where people live is a strong predictor of whether they will receive potentially life-saving cancer screenings.
A new study found that young adult cancer survivors are hospitalized 1.5 times as often as people in a control group, with higher rates for gastrointestinal and urological cancers. The study highlights the ongoing impact of cancer on young adults' lives and long-term health.
A large trial shows liquid biopsy (BEAMing technology) detects tumor genotypes not found in tissue biopsies, enabling targeted therapy selection. Regorafenib benefits patients with KRAS and PIK3CA mutations, revolutionizing colorectal cancer treatment.
Patients whose colorectal cancer is detected during a screening colonoscopy tend to live longer than those who wait until symptoms appear. The study found that these patients had cancer at an earlier stage and were more likely to survive beyond the study period, with about 55% surviving beyond the time of diagnosis.
Patients with metastatic colorectal cancer (mCRC) and quadruple wild-type genes showed significant benefit from continuing anti-EGFR therapy beyond progression. Second-line cetuximab plus FOLFOX chemotherapy improved progression-free survival, response rate, and overall survival in patients without genetic mutations.
A phase IIIb study has confirmed regorafenib's benefit in patients with previously treated metastatic colorectal cancer. The safety profile and progression-free survival were similar to phase III trial results, with a median duration of 2.5 months.
Patients with a low to healthy body weight had an average survival time of two-and-a-half months less than overweight and obese patients. The study suggests that there may be a relationship between having a lower BMI and poor treatment tolerance, putting thinner patients at risk for poor outcomes.
A pooled analysis of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab found that those with the lowest body mass index (BMI) had significantly shorter overall survival compared to other BMI categories. Progression-free survival was similar across all subgroups.
The SENRI trial found that NK1 antagonists significantly increased the inhibition rate of vomiting and nausea, especially in females. The three-drug combination therapy of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone may be a good antiemetic treatment option for oxaliplatin-based chemotherapy in patients with colorectal c...
Researchers have discovered a gene called SMOC-2 that plays a crucial role in the spread of colorectal cancer. Increased levels of SMOC-2 enable tumor cells to 'leave home' and metastasize, while blocking its activation inhibits metastasis. The gene's expression patterns also resemble those of healthy intestinal stem cells.
A recent study discovered that Daple protein is a tumor suppressor in the early stages of colorectal cancer, but may actually facilitate disease spread at later stages. Researchers found that higher levels of Daple were associated with better patient survival rates and lower tumor growth.
Researchers developed an electrochemical platform to measure DNMT1 activity, a protein linked to cancerous transformation, in crude tissue samples. The technique shows promise for early detection of colorectal cancer with high sensitivity and minimal invasion.
Researchers at St. Jude Children's Research Hospital have found a way to prevent or slow progression of colorectal cancer by boosting the activity of a protective gene called AIM2 and giving patients healthy donor bacteria.
Researchers found that reactivating a single gene turned colorectal cancer cells back into normal tissue within days, stopping tumor growth and eliminating signs of cancer. The study provides proof of principle for developing effective cancer treatments by targeting specific tumor suppressor genes.
Researchers identified two genes, ERCC1 and TS, that can predict positive response to chemotherapy and longer survival times in metastatic colorectal cancer patients. Low levels of these genes are associated with improved survival rates when treated with oxaliplatin, while high levels may require irinotecan as the first treatment choice.
A systematic review and meta-analysis of 36 observational studies found that nut consumption is associated with a decreased risk of colorectal cancer, endometrial cancer, and pancreatic cancer. However, it was not linked to type 2 diabetes.
A study of over 57,000 screenings found that higher adenoma detection rates are associated with a 53-60% lower lifetime risk of colorectal cancer and death. However, the cost-effectiveness remains uncertain despite potential complications from more frequent colonoscopies.
Researchers at the University of Arizona College of Pharmacy have discovered a potent inhibitor of colorectal cancer in mice by adding cinnamaldehyde to their diet. This compound, found in cinnamon, allows animals' cells to protect themselves against carcinogens through detoxification and repair.
Screening for colorectal cancer increased among lower-income and least-educated adults following the Affordable Care Act's removal of cost-sharing provisions. This increase was observed, particularly among Medicare-insured individuals, suggesting that ACA's provision may have contributed to the rise in screening rates.
A University of Colorado Cancer Center study found significant genetic differences between colorectal cancer tumors in young and old patients. The study identified altered gene signaling pathways, including PPAR and IGF1R, which may be involved in the development of younger CRC tumors.
A new study found cancer survivors in the US experience significant annual economic burdens, with nonelderly colorectal and breast cancer survivors facing substantial excess medical expenditures and employment disability. Elderly survivors have lower but still notable economic burdens, highlighting varying impact by age group and cance...
A drug developed in the late 1950s and abandoned due to toxicity has been revived as a treatment for advanced colorectal cancer. The drug, TAS-102, extended patients' overall survival and delayed disease progression with minimal side effects.
A phase I study found that Sym004, a double-targeting EGFR antibody, provides better outcomes than current anti-EGFR therapies in patients with resistant colorectal cancer. The treatment resulted in significant antitumor activity and improved disease-control rates.
A new animal study from Harvard Medical School suggests that a walnut-enriched diet may slow colorectal tumor growth by altering gene expression. The study found that walnuts caused significant changes in the expression profile of micro-ribonucleic acids (miRNAs) in localized colorectal cancer tissue.
A large prospective study found that consuming one ounce of nuts per week reduced the risk of colorectal cancer among women. The study, published in the European Journal of Clinical Nutrition, suggests a possible inverse association between nut consumption and colorectal cancer risk.
Following a healthy lifestyle, including diet and physical activity guidelines, is associated with improved survival when diagnosed with bowel cancer. A large study of over 500,000 participants found that men with a high lifestyle score had a lower risk of mortality, while women who breastfed also showed increased survival.
Researchers at The Hormel Institute discovered that aspirin may exert its chemopreventive effects against colorectal cancer by normalizing epidermal growth factor receptor (EGFR) expression in gastrointestinal precancerous lesions. This finding suggests EGFR as a novel target for preventing colorectal cancer.
Researchers found that a toxic mushroom-based drug can suppress the POLR2A gene in cancer cells, resulting in complete tumor regression and reduced toxicity. The study's findings provide a new therapeutic approach for human cancers with common genomic alterations.
A new therapeutic strategy has been identified for treating colorectal cancer with the BRAF mutated gene, which is associated with poor prognosis. Inhibition of endosomal activity and P45-IKKα enzyme inhibition show promise in preventing tumour growth and metastasis.
Researchers found that silibinin from milk thistle significantly slowed the growth of colorectal cancer stem cells in mice, reducing tumor size and metabolism. Re-injecting these cancer stem cells into new mice showed a loss of their potential to form aggressive tumors even without silibinin exposure.
Studies published in Journal of Cancer Survivorship found that walking three hours a week can improve hormone functioning and vitality in prostate cancer survivors. Regular physical activity also reduces symptoms of chemotherapy-induced peripheral neuropathy in colorectal cancer survivors, improving quality of life.
A new study finds that racial disparities in cancer outcomes are decreasing, with African Americans showing faster decreases in cancer mortality than Caucasians. The causes of these disparities include low education and income, as well as reduced access to quality healthcare.
Researchers from CNIO have discovered that the MCRS1 protein induces increased mTOR activity in response to excess nutrients, leading to cell growth and proliferation. This correlation was found in human colorectal cancer samples, suggesting a potential link between MCRS1 activity and disease prognosis.
A new biomarker, PAS, has been identified to predict cetuximab response in colorectal cancer (CRC) patients with wild-type K-ras. This finding could help physicians make better treatment decisions, improving patient outcomes.
The American Cancer Society's new report highlights disparities in cancer prevention and early detection efforts, including underutilized screening for colorectal and cervical cancers. Meanwhile, tobacco use remains a major cause of preventable disease and premature death, with wide variation by education and race/ethnicity.
A new study provides experimental evidence that a drug inhibiting the EphB-signaling pathway effectively suppresses intestinal tumor development. The study suggests that this knowledge may lead to novel treatments for colorectal cancer patients.
A study published in JAMA Oncology found that high fitness levels in midlife were associated with a lower risk of lung and colorectal cancer. High fitness also reduced the risk of death from these cancers, as well as cardiovascular disease death among men diagnosed with cancer.
A new study published in JNCI: Journal of the National Cancer Institute found that high marine ϖ-3 polyunsaturated fatty acid intake is associated with a lower risk of microsatellite instability (MSI)-high colorectal cancers. However, this relationship was not observed for MSI-stable (MSS) CRCs.
A multi-disciplinary team from Singapore has characterised genetic changes associated with liver metastasis in colorectal cancer, enabling the development of personalised diagnostic tests. The research could lead to improved treatment and cure rates for patients.
Researchers from the University of Melbourne found that genetic variation affects the protective effect of aspirin on bowel cancer risk. The study analyzed data from 8,624 participants and found that about 1 in 25 people do not benefit from taking aspirin, potentially increasing their risk.
A new study from Brigham and Women's Hospital found that Asian-Americans diagnosed with cancer have significantly lower cancer-specific mortality rates compared to non-Hispanic white patients. The study analyzed data from over 2.5 million patients and broke down the population into eight subgroups, revealing variations in survival rate...
A study of 19,000 individuals found that regular use of aspirin and/or NSAIDs was associated with a lower risk of colorectal cancer. However, the association differed according to specific genetic variations at chromosomes 12 and 15.
A new study found that regular use of aspirin and NSAIDs is associated with a reduced risk of colorectal cancer in those with certain genetic variations on chromosome 15. However, about 4% of participants with two rare genotypes on chromosome 12 had an increased risk of colorectal cancer.
Researchers identified genetic markers that determine who benefits from aspirin and NSAIDs in lowering colorectal cancer risk. Aspirin and NSAID use is associated with a lower risk of colorectal cancer among individuals with a specific genotype.
A team of researchers from the University of Pennsylvania has found evidence of a new culprit in colon cancer, the protein MSI2. Overexpression of MSI2 is common in colon cancer tumors and promotes tumor growth by disrupting cellular metabolism.
A new study estimates that increasing screening rates to 80% in the US by 2018 would prevent 21,000 colorectal cancer deaths annually by 2030. The initiative aims to boost screening from 58% in 2013 to 80% in 2018.
Researchers identified germline TP53 gene mutations in 1.3% of patients with early-onset colorectal cancer, comparable to the proportion attributed to APC gene mutations. The findings highlight the need for clinicians to counsel patients undergoing TP53 testing as part of multigene risk assessment.
A vegetarian diet was associated with a 22% lower risk of all colorectal cancers, and higher risks were found for non-vegetarians. Vegetarian diets similar to those studied may be important for primary prevention of colorectal cancers.